Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
8
×
life sciences
national blog main
clinical trials
national top stories
boston
biotech
new york blog main
drugs
san diego blog main
san francisco blog main
deals
new york top stories
patisiran
rna interference
san diego top stories
san francisco top stories
startups
akcea therapeutics
alnylam pharmaceuticals
atlas venture
cancer
fda
gene therapy
inotersen
onpattro
regeneron pharmaceuticals
tafamidis
wisconsin blog main
wisconsin top stories
accelerator
acute hepatic porphyrias
adeno-associated virus
airbnb
akin akinc
alexion pharmaceuticals
allosteric
alnylam pharmaceutials
amazon web services (aws)
What
ago
8
×
medicines
alnylam
drug
fda
rna
therapeutics
years
biotechs
companies
disease
genetic
interference
long
medicine
patients
rare
rnai
abandoning
adding
address
adds
admits
aiming
akcea
allosteric
amyloidosis
approval
approve
approved
attr
available
awaits
baggage
balance
battle
big
biological
build
classes
Language
unset
Current search:
ago
×
" boston top stories "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision